Managing Iron Deficiency Anemia: Pathophysiologic Considerations and Treatment Options

Program date: Friday, 12/06/2013 From 12:30PM to 3:45PM

Registration & Box Lunch: 12:30-1:00PM
Symposium: 1:00-3:45PM

Program location:
New Orleans Marriott
Mardi Gras Ballroom A-D
New Orleans, LA

Program Overview

Iron deficiency is the most common nutritional disorder, and the World Health Organization estimates that approximately 3 billion people around the world with anemia suffer from iron deficiency anemia (IDA). Due to the complex pathophysiology of IDA and the unfounded fear regarding the safety of parenteral iron replacement therapies, IDA remains an inadequately managed condition. A number of causes of IDA have been reported, and identifying the underlying cause of iron deficiency is essential for effective management. A clear understanding of the inadequacies of the currently available iron panel tests, the pathophysiology of IDA, iron refractory IDA, limitations of oral iron replacement therapies, and the safety, efficacy, and convenience of some of the currently available intravenous iron replacement therapies are all of paramount importance to effectively manage patients with cancer- or chemotherapy-induced anemia and those with other non-cancer related IDA including pregnancy. The expert faculty will provide an in-depth review of these topics and will provide insights regarding the safe and effective use of intravenous iron replacement therapies to appropriately and adequately manage IDA. An audience response system will be used throughout the program to keep the audience engaged, and the program will end with a question and answer session where the participants can ask questions to the expert faculty.

CME INFORMATION -

Educational Objectives

After completing this activity, the participant should be better able to:

  1. Manage patients appropriately using iron replacement therapies based on a thorough understanding of the underlying pathophysiological disturbances
  2. Assess the use of intravenous iron replacement therapies in managing patients with iron deficient anemia based upon safety, efficacy, and convenience data
  3. Evaluate the current evidence regarding the incidence and clinical nature of serious adverse events associated with intravenous iron replacement therapies

Agenda

 

12:30-1:00PM

Registration and Box Lunch

1:00-1:35PM

Intravenous Iron: History, Administration, and Safety

Michael Auerbach, MD, FACP

1:35-1:55PM

Iron Deficiency Anemia: Overview and Pathophysiology

Michael A. McDevitt, MD, PhD

1:55-2:30PM

Iron Replacement Therapy: Non-cancer Conditions

Michael Auerbach, MD, FACP

2:30-2:50PM

 

Iron Refractory Iron Deficiency Anemia

Michael A. McDevitt, MD, PhD

2:50-3:25PM

Iron Replacement Therapy: Cancer- and Chemotherapy-induced Anemia

Michael Auerbach, MD, FACP

3:25-3:45PM

Q & A

All Faculty

Target Audience

This activity has been designed for hematologist oncologists and other healthcare professionals who are interested in the management of patients with iron deficiency anemia (IDA).

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and ACCELMED. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact ACCELMED prior to the live event at (877) 374-8323.

Fee Information

There is no registration fee for attending this symposium; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Additional program details and logistical information will be sent to all participants in a registration confirmation.

Friday Satellite Symposium on Managing Iron Deficiency Anemia: Pathophysiologic Considerations and Treatment Options, preceding the 55th ASH Annual Meeting.